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INTRODUCTION
Approximately 20% to 30% of breast cancers are human 
epidermal growth factor receptor 2 (HER2) overexpressing or 
amplifying carcinomas, and these tumors were associated 
with poor survival before the era of targeted therapy [1]. In-
corporation of trastuzumab into systemic chemotherapy has 
shown improved survival of patients with these aggressive tu-
mors in the metastatic and adjuvant setting [2,3]. However, 
certain HER2-positive cancers eventually develop resistance 
to therapy and large number of recurrent or metastatic tu-
mors are still incurable despite the existence of newly devel-
oped HER2-targeted therapies, such as lapatinib, pertuzumab, 
and trastuzumab emtansine [4].
Evading immune destruction is one of the hallmarks of 
cancer and immunity related molecules can be targets for anti-
cancer drugs [5]. One mechanism through which trastu-
zumab exerts its function is antibody-dependent cellular cyto-
toxicity (ADCC), and therefore, evasion from ADCC has 
been suggested as a possible resistance mechanism to targeted 
therapy [6,7]. It has been reported that anti-HER2 CD4+ Th1 
response, CD8+/FOXP3+ tumor infiltrating lymphocyte 
(TIL) ratio, or tumor-associated lymphocytes can be useful 
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Purpose: The present study aimed to examine the clinical impli-
cations of CD4, CD8, and FOXP3 expression on the prognosis 
of human epidermal growth factor receptor 2 (HER2)-positive 
breast cancer using a web-based database, and to compare the 
immunohistochemical expression of T-lymphocyte markers us-
ing primary and metastatic HER2-positive tumor tissues before 
and after HER2-targeted therapy. Methods: Using the cBioPortal 
for Cancer Genomics and Kaplan-Meier plotter, the mRNA ex-
pression, association between T-lymphocyte markers, and sur-
vival in HER2-positive cancers were investigated according to 
various cutoff levels. Immunohistochemistry analysis was per-
formed using paired primary and metastatic tissues of 29 HER2-
positive tumors treated with systemic chemotherapy and HER2-
directed therapy. Results: HER2 mRNA was mutually exclusive of 
T-lymphocyte markers, and a significant correlation between T-
cell markers was observed in the cBioPortal for Cancer Genomics. 
According to analysis of the Kaplan-Meier plotter, the impact 
of T-lymphocyte marker expression on survival was sta-
tistically insignificant in clinical HER2-positive tumors, irrespec-
tive of the cutoff levels. However, in the intrinsic HER2-positive 
subtype, the individual analyses of T-cell markers except for 
FOXP3 and combined analysis showed significantly favorable 
survival irrespective of cutoff points. Although the small clinical 
sample size made it difficult to show the statistical relevance of 
immunohistochemistry findings, good responses to neoadjuvant 
treatments might be associated with positive expression of com-
bined T-lymphocyte markers, and approximately half of the sam-
ples showed discordance of combined markers between base-
line and resistant tumors. Conclusion: T-lymphocyte markers 
could be favorable prognostic factors in HER2-positive breast 
cancers; however, a consensus on patient section criteria, de-
tection methods, and cutoff value could not be reached. The re-
sistance to HER2-directed therapy might involve different and 
personalized mechanisms, and further research is required to 
understand the association between immune function and HER2 
expression and to overcome the resistance mechanisms to 
HER2-targeted therapies.
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predictors of the pathological response to neoadjuvant che-
motherapy [8-10]. Data from clinical trials suggested that pa-
tients with CD8+ T cells or increased number of TILs might 
be associated with better survival when trastuzumab was ad-
ministered [11,12]. However, methodological issues concern-
ing the evaluation of TILs have been debated [13]. Recently, 
an international TILs Working Group published recommen-
dations for the evaluation of TILs in breast cancer; however, a 
formal recommendation for a clinically relevant TIL threshold 
has not yet been suggested [14]. 
This study aimed to explore the expression status and the 
association between T-lymphocyte markers as well as to in-
vestigate the prognostic role of CD4, CD8, and forkhead P3 
(FOXP3) expression in HER2-positive breast cancer using a 
web-based database. Clinically clear cutoff values for T-cell 
marker expression have not been established and various cut-
off levels were included in the web-based analysis. In addition, 
we compared the immunohistochemical expressions of CD4, 
CD8, and FOXP3 before and after HER2-targeted therapy in 
primary or metastatic HER2-positive breast cancer patients to 
better understand the clinical implications of T-cell markers 
on the mechanisms of resistance to targeted therapy.
METHODS
Web-based bioinformatics analysis
Genomic analysis was performed for exploring the associa-
tions between HER2 and T-lymphocytes markers of CD4, 
CD8, and FOXP3 through the cBioPortal for Cancer Genomics 
(http://www.cbioportal.org) which provides web-based vi-
sualization, analysis and download of large-scale cancer ge-
nomic datasets including The Cancer Genome Atlas (TCGA) 
data [15,16]. We used the Breast Invasive Carcinoma (TCGA, 
Provisional) dataset, which includes mRNA expression and 
clinicopathological information of 1,105 samples obtained 
from 1,098 patients in May 2016. The RNA Seq Version 2 
(RNA-Seq by Expectation Maximization [RSEM]) for each 
gene was selected to generate an OncoPrint in the cBioPortal 
for visualizing the genetic alteration and to investigate the 
mutual exclusivity or co-occurrence among alterations in bio-
markers of whole analyzed samples. We downloaded the 
mRNA expression data of CD4, CD8 and FOXP3 and clinical 
HER2 information data to explore the associations between 
T-lymphocyte markers in HER2-positive breast cancers. Us-
ing variables of immunohistochemistry (IHC)–HER2 and 
HER2 fluorescence in situ hybridization (FISH) status in the 
TCGA dataset as variables, IHC-HER2 positive cases, HER2 
FISH status positive cases, or IHC-HER2 equivocal cases with 
HER2 FISH-positivity were considered to have HER2-positive 
tumors.
The probability of relapse-free survival according to bio-
markers was calculated using the Kaplan-Meier plotter data-
base (http://kmplot.com/analysis) [17]. It is an online tool that 
allows analysis of the effects of 54,675 genes on survival by us-
ing 10,188 cancer samples including 4,142 breast cancer pa-
tients with a mean follow-up duration of 69 months in May 
2016. Survival and gene expression data were derived from 
the Gene Expression Omnibus (Affymetrix microarray only), 
European Genome-phenome Atlas, and TCGA. The Affymetrix 
probe set IDs selected for the evaluation of CD4, CD8, and 
FOXP3 expressions were 203547_at, 205758_at, and 224211_
at, respectively, in the present study. To analyze the prognostic 
value of a particular gene, the patient samples were split into 
two groups according to various quantile expressions of the 
proposed biomarker. Multiple genes were also analyzed 
through a multigene classifier using the mean expression lev-
els of selected biomarkers. Hazard ratio with 95% confidence 
interval and log-rank p-value were calculated and displayed 
on the webpage.
Patient selection
Using tissue blocks previously archived from HER2-positive 
breast cancer patients who received systemic chemotherapy 
combined with trastuzumab or tyrosine kinase inhibitors at the 
Severance Hospital of Yonsei University College of Medicine, 
Seoul, Republic of Korea, between January 2007 and December 
2011, the expressions of CD4, CD8, and FOXP3 on IHC were 
investigated to compare the T-lymphocytes markers before 
and after targeted therapy [18]. Briefly, tumor samples before 
and after HER2-directed therapies were available in most 
cases; however, five out of 29 patients received targeted therapy 
in the neoadjuvant setting and achieved pathologic complete 
response (pCR) after curative surgery. Therefore, tissue blocks 
after targeted therapy could not be obtained and the five patients 
with pCR were defined as good responders in the present 
study. Of 29 patients, 24 eventually experienced disease pro-
gression or recurrence despite the administration of targeted 
therapy and were defined as poor responders in the study. The 
baseline expression of T-lymphocyte markers between five 
good and 24 poor responders were compared. Among the 24 
poor responders, the T-cell markers of six recurrent or meta-
static tumor samples could not be evaluated. Thus, using 
18-matched baseline and resistant tumor samples before and 
after targeted therapy, the expression of T-lymphocyte mark-
ers was compared. In total, 47 tissue blocks from 29 patients 
were analyzed. The present study was approved by the Institu-
tional Review Board of Severance Hospital, Yonsei University 
Health System, Seoul, Republic of Korea (IRB number: 4- 
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2013-0390). The requirement for written informed consent 
was waived.
Clinicopathological parameters and immunohistochemical 
staining
Clinicopathological information including treatment mo-
dalities or expression of hormone receptors and HER2 was ob-
tained from the review of medical records and pathology re-
ports. Chemotherapeutic agents of 29 patients were paclitaxel 
in 14 patients, anthracycline plus cyclophosphamide followed 
by taxane in 11, anthracycline plus taxane in two, and anthra-
cycline plus cyclophosphamide in one. One patient was treated 
with cyclophosphamide, methotrexate, and 5-fluorouracil due 
to intolerability after first administration of anthracycline plus 
cyclophosphamide. Tumors with ≥ 1% nuclear-stained cells by 
IHC were considered positive for estrogen receptor (ER) and 
progesterone receptor according to the American Society of 
Clinical Oncology/College of American Pathologists (ASCO/
CAP) guidelines [19]. The HER2 stains were scored as 0, 1+, 
2+, or 3+ according to ASCO/CAP guidelines [20]. In cases 
with a HER2 2+ result, FISH was performed using a PathVysion 
HER2 DNA Probe Kit (Vysis, Downers Grove, USA) and 
HER2 gene amplification was defined as a HER2 gene/chro-
mosome 17 copy number ratio ≥ 2.0 according to ASCO/CAP 
guidelines [20]. HER2 was considered positive in cases with an 
IHC score of 3+ or gene amplification by FISH.
After reviewing the archival hematoxylin and eosin stained 
slides, IHC was performed using the whole sections of forma-
lin-fixed, paraffin-embedded tissue blocks. Briefly, 3-µm thick 
whole sections were deparaffinized and rehydrated in usual 
manner. Antigen retrieval was performed using an electronic 
pressure cooker for 10 minutes in Trilogy buffer (Cell Marque 
Co., Rocklin, USA). After treatment with hydrogen peroxide 
block solution for 10 minutes, background staining was blocked 
by incubation in Ultra V Block solution (Thermo Scientific/
Lab Vision, Fremont, USA) for 5 minutes at room tempera-
ture. After incubation with primary antibodies against CD4 
(diluted 1:100, M3352; Spring Bioscience Corp., Pleasanton, 
USA), CD8 (diluted 1:100, M3162; Spring Bioscience Corp.), 
and FOXP3 (diluted 1:50, AB20034; Abcam, Cambridge, 
UK), immunodetection was carried out using the UltraVision 
LP detection system (Thermo Scientific/Lab Vision) accord-
ing to the manufacturer’s instructions. Color was developed 
with 3,3´ -diaminobenzidine and slides were counterstained 
with Harris hematoxylin. The primary antibody incubation 
step was omitted in the negative control.
Interpretation of the immunohistochemical staining was 
performed blindly to obtain clinical data of the patients. Arbi-
trary scoring rules of CD4 and CD8 lymphocytes were as fol-
lows: 1+, 0% to 33% staining; 2+, 34% to 66% staining; and 
3+, 67% to 100% staining. FOXP3 was scored by counting the 
number of positively stained cells, which was expressed as a 
percentage of total lymphocytes. The cutoff value for FOXP3 
positivity was ≥ 10% of the stained cells.
Statistical analysis
Web-based bioinformatics statistics was automatically cal-
culated by each website and the results were displayed on the 
webpage. The downloaded TCGA dataset was analyzed using 
correlation coefficient to explore the association between T-
lymphocyte markers in HER2-positive tumors. Differences 
between the discrete variables in patients of Severance Hospi-
tal were evaluated by using the Fisher exact test. For the com-
parison of the means in the case of continuous numerical 
data, an independent two-sample t-test was used. A p-value 
< 0.05 was considered statistically significant. All statistical 
analyses were performed using SPSS version 23.0 (IBM Corp., 
Armonk, USA).
RESULTS
We first explored the mRNA expression status using the 
TCGA Provisional dataset, and information about the bio-
marker expression was obtained for 1,100 samples from 1,093 
patients. Genetic alteration of CD4, CD8, FOXP3, and HER2 
including mRNA upregulation and downregulation was not-
ed in 4%, 4%, 4%, and 16% of whole samples, respectively 
(Supplementary Figure 1, available online). One or more 
genes were altered in 250 patients (22.7%). There was no 
mRNA downregulation in T-lymphocyte markers. When the 
mutual exclusivity and co-occurrence among these four bio-
markers was investigated, the HER2 gene showed a tendency 
towards mutual exclusivity with CD4 (p= 0.227; log odds ra-
tio = -0.464), CD8 (p = 0.290; log odds ratio = -0.383), and 
FOXP3 (p= 0.328; log odds ratio= -0.302). However, a ten-
dency towards co-occurrence among T-lymphocyte markers 
was shown in whole samples (p< 0.001; log odds ratio, > 3). 
The TCGA Provisional dataset also included clinical HER2-
associated variables and among them, variables of IHC-HER2 
and HER2 FISH status were relatively complete data filled up. 
According to the clinical variables of IHC-HER2 and HER2 
FISH status, the mRNA expression of T-cell markers was de-
rived (Supplementary Figure 2, available online) and there 
was no significant association between T-lymphocyte marker 
expression and clinical HER2 information.
After downloading the mRNA expression data of T-lympho-
cyte markers and clinical HER2 information data of IHC-HER2 
and HER2 FISH status, the association between T-lymphocyte 
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markers was reinvestigated in HER2-positive tumors (Figure 1). 
According to the combined data of IHC-HER2 and HER2 FISH 
status, 198 out of 1,100 samples (18.0%) were clinically catego-
rized as HER2-positive tumors. The TCGA dataset included 759 
(59.0%) HER2-negative tumors and 143 (13.0%) cases with 
missing HER2 data. Pearson correlation coefficient between 
CD4 and CD8, CD4 and FOXP3, and CD8 and FOXP3 was 
0.585 (p<0.001), 0.695 (p<0.001), and 0.602 (p<0.001), respec-
Figure 1. Association between CD4, CD8, and forkhead P3 (FOXP3) in 
human epidermal growth factor receptor 2 (HER2)-positive breast can-
cers. Among 198 patients with HER2-positive breast cancer consider-
ing immunohistochemistry-HER2 and HER2 fluorescence in situ hybrid-
ization status variables from the The Cancer Genome Atlas Provisional 
dataset, the association between (A) CD4 and CD8A, (B) CD4 and 
FOXP3, and (C) CD8A and FOXP3 is drawn. 
RSEM=RNA-Seq by Expectation Maximization; V2=version 2.
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Table 1. Survival analysis according to T-lymphocyte markers using different cutoff levels in HER2-positive cancer defined by category of HER2 status 
from the Kaplan-Meier plotter
Split patients
CD4 CD8 FOXP3
No. of 
patients*
HR† 95% CI
Log-rank 
p
No. of 
patients*
HR† 95% CI
Log-rank 
p
No. of 
patients*
HR† 95% CI
Log-rank 
p
Lower quartile  42:126 0.59 0.34–1.02 0.058  42:126 0.73 0.41–1.29 0.275   39:111 1.03 0.56–1.90 0.929
Lower tertile  55:113 0.6 0.36–1.02 0.058  55:113 0.83 0.48–1.43 0.492   50:100 1.09 0.61–1.95 0.781
Median 84:84 0.99 0.59–1.67 0.983 84:84 1.04 0.61–1.74 0.896  75:75 1.01 0.58–1.75 0.973
Upper tertile 113:55 1.19 0.69–2.05 0.534 113:55 0.56 0.31–1.03 0.060 100:50 0.67 0.36–1.24 0.202
Upper quartile 126:42 1.49 0.84–2.64 0.168 128:40 0.51 0.25–1.03 0.057 112:38 0.64 0.32–1.27 0.198
HER2=human epidermal growth factor receptor 2; HR=hazard ratio; CI=confidence interval.
*Number of patients was presented as patients having low expression versus those having high expression; †Hazard ratio of patients having high expression of 
biomarker.
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tively. The corresponding Spearman’s rho values were 0.750 
(p<0.001), 0.761 (p<0.001), and 0.713 (p<0.001), respectively.
Next, the prognostic value of T-lymphocyte markers in 
HER2-positive breast cancer was examined using the Kaplan-
Meier plotter. Since the clear cutoff points of T-cell markers 
were not determined, the relapse-free survival according to 
different levels of T-lymphocyte markers was analyzed. Re-
sults of the survival analysis using a single marker for 168 
HER2-positive cancers defined by HER2 status are summa-
rized in Table 1 and for 208 HER2-positive subtypes defined 
by intrinsic subtype in Table 2. In HER2-positive cancers de-
fined by HER2 status, as cutoff levels of biomarker increased, 
the hazard ratio gradually increased in CD4, increased and 
then decreased in CD8, and gradually decreased in FOXP3. 
However, there was no statistical significance of T-lymphocyte 
markers on survival (Table 1). In the HER2-positive intrinsic 
Table 2. Survival analysis according to T-lymphocyte markers using different cutoff levels in HER2-positive subtype defined by category of intrinsic 
subtype from the Kaplan-Meier plotter
Split patients
CD4 CD8 FOXP3
No. of 
patients*
HR† 95% CI
Log-rank 
p
No. of 
patients*
HR† 95% CI
Log-rank 
p
No. of 
patients*
HR† 95% CI
Log-rank 
p
Lower quartile   52:156 0.57 0.37–0.89  0.013   52:156 0.41 0.27–0.64 <0.001  38:111 0.76 0.45–1.28 0.294
Lower tertile   69:139 0.45 0.3–0.68 <0.001   69:139 0.53 0.35–0.8  0.002  50:99 0.65 0.4–1.05 0.074
Median  104:104 0.52 0.34–0.79  0.002  104:104 0.52 0.34–0.8  0.003  74:75 0.64 0.4–1.03 0.063
Upper tertile 139:64 0.68 0.43–1.09  0.108 139:64 0.57 0.35–0.92  0.021 101:48 0.93 0.56–1.54 0.766
Upper quartile 156:52 0.62 0.36–1.06  0.076 156:52 0.57 0.33–0.98  0.038 114:35 0.74 0.41–1.33 0.315
HER2=human epidermal growth factor receptor 2; HR=hazard ratio; CI=confidence interval.
*Number of patients was presented as patients having low expression versus those having high expression; †Hazard ratio of patients having high expression of 
biomarker.
Figure 2. Survival curves using a multigene 
classifier in human epidermal growth factor re-
ceptor 2 (HER2)-positive subtype defined by 
category of intrinsic subtype from the Kaplan-
Meier plotter. Plots were derived from the Kaplan-
Meier plotter. Intrinsic subtypes are based on 
the 2013 St. Gallen criteria using the expres-
sion of HER2, Estrogen receptor (ER), and Ki-
67 in the Kaplan-Meier plotter and HER2-
positive intrinsic subtype is defined as HER2+/
ER–. In 239 patients with the HER2-positive in-
trinsic subtype, patients are split by (A) lower 
quartile, (B) lower tertile, (C) median, (D) upper 
tertile, and (E) upper quartile. 
HR=hazard ratio.
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subtype, higher expression of CD4 and CD8 was significantly 
associated with favorable survival irrespective of cutoff levels 
(Table 2). Only when the patients were split by upper tertile 
and upper quartile of CD4, log-rank p-value was not statisti-
cally significant. Irrespective of cutoff levels, the hazard ratio 
of higher FOXP3 expression was less than 0.1, resulting in no 
statistical significance.
Since the T-lymphocyte markers were significantly co-oc-
curring in prior TCGA Provisional analysis, we reanalyzed 
survival using a multigene classifier for considering T-lym-
phocyte markers all together. Similar to the results in Table 1, 
there was no statistical significance in HER2-positive cancers 
defined by HER2 status (log-rank p> 0.05) (Supplementary 
Figure 3, available online). In the HER2-positive intrinsic sub-
types, however, higher expression of T-lymphocyte markers 
was associated with favorable survival irrespective of cutoff 
levels except for the median value (Figure 2).
Finally, we explored the clinical implications of T-cell mark-
ers on the resistance to HER2-directed therapy by using tissue 
blocks of previous patient cohorts. Of the 47 tissue blocks, 30 
(63.8%) were obtained from the breast. Tissue samples were 
obtained from locoregional sites in nine cases (19.1%). The 
lungs, brain, and bone or soft tissues were obtained in three 
(6.4%), three (6.4%), and two cases (4.3%), respectively. Posi-
tive IHC staining of the biomarkers are shown in Figure 3. 
Clinicopathological characteristics and expression of T-lym-
phocyte markers are presented according to the response to 
targeted therapy in Table 3. When the positive criteria were 
defined as CD4 3+, CD8 ≥ 2+, and FOXP3 ≥ 10% consider-
ing frequency of marker expression in this study, all good re-
sponders showed positive expression of T-lymphocyte mark-
ers one or more, although there was no statistical significance. 
Among poor responders, 18-matched baseline and resistant 
tumor samples before and after targeted therapy were com-
pared considering combined 3 T-lymphocyte markers status. 
At baseline, four patients showed negative results for all 3 T-
lymphocyte markers expression but changed to positive status 
Table 3. Comparison of T-lymphocyte markers and clinicopathological 
characteristics between patients with good and poor response to tar-
geted therapy
Characteristic
Poor 
responder 
group 
(n=24) 
No. (%)
Good 
responder 
group 
(n=5) 
No. (%)
Total p-value*
Age (yr)† 46.4±10.6 48.4±10.9 46.8±10.5  0.708‡
Initial stage
   II 11 (45.8) 2 (40.3) 13 (44.8) >0.999
   III 10 (41.7) 3 (60.0) 13 (44.8)  
   IV 3 (12.5)   3 (10.3)  
Hormone receptors     
   ER (+) or PR (+) 13 (54.2) 3 (60.0) 16 (55.2) >0.999
   ER (–)/PR (–) 11 (45.8) 2 (40.0) 13 (44.8)
Regimens of targeted 
   therapy
   Trastuzumab based 16 (66.7) 4 (80.0) 20 (69.0) >0.999
   TKI± trastuzumab 8 (33.3) 1 (20.0)  9 (31.0)  
CD4     
   1+ 2 (8.3) 0 2 (6.9)  0.187
   2+ 10 (41.7) 0 10 (34.5)  
   3+ 12 (50.0) 5 (100) 17 (58.6)  
CD8     
   1+ 10 (41.7) 2 (40.0) 12 (41.4)  0.415
   2+ 13 (54.2) 2 (40.0) 15 (51.7)  
   3+ 1 (4.2) 1 (20.0) 2 (6.9)  
FOXP3     
   Negative (0%–9%) 15 (62.5) 3 (60.0) 18 (62.1) >0.999
   Positive (≥10%)  9 (37.5) 2 (40.0) 11 (37.9)  
CD4/CD8/FOXP3
   All-negative  5 (20.8) 0  5 (17.2)  0.553
   Either-positive 19 (79.2) 5 (100) 24 (82.8)
ER=estrogen receptor; PR=progesterone receptor; TKI= tyrosine kinase in-
hibitors; FOXP3=forkhead P3.
*Fisher exact test; †Mean±SD; ‡Independent two samples t-test.
Figure 3. Immunohistochemical expression of CD4, CD8, and forkhead P3 (FOXP3) in human epidermal growth factor receptor 2 (HER2)-positive 
breast cancer tissues (×200). Immunohistochemical staining reveals that tumor infiltrating lymphocytes adjacent to cancer cells (black arrows) are re-
active to CD4 (red arrow) (A), CD8 (red arrow) (B), and FOXP3 (red arrow) (C).
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of either biomarker at recurrent or metastatic sample. At baseline, 
14 cases were positive for ≥ 1 T-lymphocyte markers and re-
mained positive in 10 cases at recurrent or metastatic samples. 
However, four patients with positive status of either marker at 
baseline changed to negative expression of all T-cell markers 
to target recurrent or metastatic samples (Fisher exact test, 
p= 0.524). There was no case of all negative markers at base-
line and recurrent samples both concordantly. Discordant 
findings of combined markers between baseline and resistant 
tumors were noted in eight of 18 samples (44.4%).
DISCUSSION
In the present study, HER2 was mutually exclusive with T-
lymphocyte markers and significant correlation between T-
cell markers was observed in HER2-positive tumors. Accord-
ing to the web-based bioinformatics analysis, there was no 
statistical importance of individual or combined T-cell mark-
ers on survival in clinically determined HER2-positive tumor 
irrespective of cutoff levels of biomarkers. In the HER2-posi-
tive intrinsic subtype, however, CD4 and CD8 were deter-
mined to have significantly positive association with survival; 
statistical significance remained when combined T-lympho-
cyte markers were considered irrespective of cutoff levels. Al-
though small clinical sample size made it difficult to show the 
statistical importance of IHC study, good responders to neo-
adjuvant chemotherapy with targeted therapy may be associ-
ated with positive expression of combined T-lymphocyte 
markers. Discordance of combined markers between the 
baseline and resistant tumors in approximately half of the 
samples suggested that individualized resistance mechanisms 
might be involved in HER2-directed therapy. 
A recent systematic review showed that the magnitude of 
TILs was variable within and between breast cancer subtypes 
and that lymphocyte-predominant breast cancer, CD8+ T-
cells, and FOXP3+ TILs were 16% (range, 11%–24%), 61% 
(range, 40%–83%), and 67% (range, 61%–74%) in HER2-pos-
itive subtype, respectively [21]. In the present study, mRNA 
expression of CD4, CD8, and FOXP3 was not different ac-
cording to HER2 status of the TCGA dataset, but there was a 
significant correlation between T-cell markers. In addition, 
previous evidence have supported the prognostic and predic-
tive roles of TILs in breast cancers [13,14,22,23]. Our study 
also suggested a possible prognostic role of T-lymphocyte 
markers measured at mRNA levels in HER2-positive tumors. 
However, patient selection remains a key issue, and signifi-
cance was shown only in ER-negative and HER2-positive 
subtype defined by intrinsic subtype.
There should be an agreement on the standardization of 
some methodological problems before the application of T-
cell markers in routine clinical practice. Multicenter interna-
tional ring studies by the international Immuno-oncology 
Biomarker Working Group demonstrated that reproducible 
evaluation of TILs using slides is feasible and the software-
guided image evaluation is useful [24]. Recommendations by 
an international TILs working group described that it is still 
unknown whether RNA or protein classification of TILs 
shows better performance of prognostic or predictive value 
than slide morphology and that further evidence of detecting 
specific subpopulations by IHC is necessary [14]. In addition, 
our mRNA analysis could not discriminate the stromal and 
intratumoral TILs status although TILs Working Group rec-
ommended the percentage in the stromal compartment. More 
evidence is required for the clinical use of TILs.
A consensus should be reached on the cutoff levels for de-
fining the clinically beneficial groups of TILs. The interna-
tional TILs Working Group 2014 recommended no formal 
thresholds for clinically relevant TILs because a valid method-
ology was more important [14]. In the present study, both 
single and combined T-lymphocyte markers were significant 
prognostic factors irrespective of the cutoff values for mRNA 
expression. However, predictive cutoff levels could not be in-
vestigated. The FinHER and NCCTG N9831 studies suggest-
ed that increased immune function could be a predictor of re-
sponse to trastuzumab [12,25]. Nevertheless, TILs or immu-
nity status should not be used to select the indications for tar-
geted therapy at present [14].
Several mechanisms of resistance to targeted therapies have 
been suggested including escape from ADCC; alteration in 
HER2 (known as p95-HER2); expression of other growth fac-
tor signal receptors such as epidermal growth factor receptor, 
HER3, and insulin-like growth factor-1 receptor; cross-talk 
between ER and HER2 signaling; and upregulation of PI3K-
AKT-mTOR pathway [6,7,26]. The discordance in the expres-
sion rates of T-lymphocyte markers between primary and 
metastatic tissues have not been fully understood, but our 
study demonstrated that half of the samples showed discor-
dant findings. Although it is likely that different complex 
mechanisms coexist, most studies evaluated each biomarker 
including the ones in the present study; overcoming this hur-
dle is a future challenge [7].
Limitations of the present study were that mRNA expres-
sion and IHC staining were currently not recommended for 
assessing T-lymphocyte marker expression, and that indepen-
dent validation and large clinical sample size were required for 
verifying their roles as prognostic and predictive biomarkers. 
There are many other subpopulations of immune cells or vari-
ous immune markers including CD3; however, we have only 
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applied 3 markers. Further studies are required for the applica-
tion of immune function to daily practice.
In conclusion, the present study attempted to investigate the 
clinical implications of CD4, CD8, and FOXP3 on the survival 
of patients with HER2-positive breast cancers using different 
patient selection criteria and various cutoff levels based on a 
web-based database. A certain proportion of T-lymphocyte 
marker expression between primary and resistant tissues pre-
sented discordant findings, which suggested different and 
personalized resistance mechanisms to targeted therapy. In 
the era of wide use and focus on development of HER2-di-
rected therapies, the association of immune function with 
HER2 pathway and setting up diagnostic and therapeutic 
strategies for overcoming resistance mechanisms to HER2-
targeted therapies is imperative.
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